Select Bibliography

Filter by any of these (after searching):

Harris, Lyndsay N.

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 7 items

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib

Carey, Lisa A. , Berry, Donald A. , Cirrincione, Constance T. ... - - J Clin Oncol - 2016

Manuscript - Primary - Primary - Breast - CALGB-40601

Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831

Dueck, Amylou C. , Reinholz, Monica M. , Geiger, Xochiquetzal J. ... - - Clin Cancer Res - 2013

Manuscript - Secondary - Primary - Breast - NCCTG-N9831

Topoisomerase IIα Amplification Does Not Predict Benefit From Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy in HER2-Amplified Early Breast Cancer: Results of CALGB 8541/150013

Harris, Lyndsay N. , Broadwater, Gloria , Abu-Khalaf, Maysa ... - - J Clin Oncol - 2009

Manuscript - Secondary - Primary - Correl Sci NOS - CALGB-150013 , CALGB-8541

Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial

Perez, Edith A. , Dueck, Amylou C. , McCullough, Ann E. ... - - J Clin Oncol - 2013

Manuscript - Secondary - Primary - Breast - NCCTG-N9831

Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria

Perez, Edith A. , Dueck, Amylou C. , McCullough, Ann E. ... - - J Natl Cancer Inst - 2012

Manuscript - Secondary - Primary - Breast - NCCTG-N9831

C-MYC Alterations and Association With Patient Outcome in Early-Stage HER2-Positive Breast Cancer From the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial

Perez, Edith A. , Jenkins, Robert B. , Dueck, Amylou C. ... - - J Clin Oncol - 2011

Manuscript - Secondary - Primary - Breast - NCCTG-N9831

HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial

Perez, Edith A. , Reinholz, Monica M. , Hillman, David W. ... - - J Clin Oncol - 2010

Manuscript - Secondary - Primary - Breast - NCCTG-N9831